Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | chemokine (C-C motif) receptor 4 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | growth hormone secretagogue receptor type 1 | chemokine (C-C motif) receptor 4 | 360 aa | 316 aa | 22.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0136 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0121 | 0.7743 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0068 | 0 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0136 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0136 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0136 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0069 | 0.0151 | 0.0151 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0136 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0136 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0084 | 0.2407 | 0.2407 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0136 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0136 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0136 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0136 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0136 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0136 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0136 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0121 | 0.7743 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0136 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0136 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0068 | 0 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0084 | 0.2407 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0136 | 1 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0136 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0136 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0136 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0136 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0136 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0136 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 4.7 | Antagonist activity at human CCR4 expressed in CHO cell membranes by [35S]-GTPgammaS radioligand competition assay | ChEMBL. | 24909677 |
pA2 (binding) | Antagonist activity at CCR4 in human whole blood assessed as F-actin polymerization in CD4+ CCR4+ lymphocytes by phalloidin staining based flow cytometry | ChEMBL. | 24909677 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.